Palavra-chave: CHRONIC MYELOID LEUKEMIA

TK INHIBITORS F359V TRANSPORTER GENES CML AUTOGRAFTING IMATINIB-RESISTANT OR-INTOLERANT MUTATION GLEEVEC DASATINIB-TREATED HMGCLL1 CYTARABINE IMATINIB-RESISTANT NILOTINIB EBMT RISK SCORES TREATMENT-FREE REMISSION NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PH CHROMOSSOME DISCONTINUATION EXON 6 POLYMORPHISMS FEDERAL UNIVERSITY OF MINAS GERAIS PERIPHERAL BLOOD STEM CELL TRANSPLANTS MITOXANTRONE DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY AUTOGRAFTING OF PERIPHERAL-BLOOD BCR-ABL GENE EXPRESSION PROFILE DHPLC BONE MARROW TRANSPLANTATION LASOR CHRONIC PHASE START IMATINIB MESILATE IRS-1 EXPRESSION PF P190 BRAZILIAN MEDICAL ASSOCIATION COVID19 TYROSINE KINASE PROGRESSION-FREE SURVIVAL EXPANDING NILOTINIB ACESS IN CLINICAL TRIALS DASATINIB IMATINIB RESISTANCE EBMT CLINICAL TRIAL T315I K562 CELLS B3A2 STEM CELL TRANSPLANTATION IMATINIB TYROSINE KINASE INHIBITORS SUBOPTIMAL RESPONSES EUTOS SCORE RT-PCR FISH INTERFERON-ALPHA PHASE 2 NEW DRUGS SECOND-GENERATION D-HPLC OCULAR MOLECULAR MOLECULAR RESPONSE BCR-ABL1 P190, P120, P230 T315L ENESTND STATE UNIVERSITY OF CAMPINAS CYTOGENETIC JAK2 V617F